A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-label Period on the Recommended Dose

Trial Profile

A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-label Period on the Recommended Dose

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Fostemsavir (Primary) ; Atazanavir; Raltegravir; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; ViiV Healthcare
  • Most Recent Events

    • 04 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 16 Aug 2017 This trial has been completed in Germany. (end date: 2017-05-12).
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top